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Background Diarrhoea remains a leading cause of morbidity and mortality but is
difficult to measure in epidemiological studies. Challenges include
the diagnosis based on self-reported symptoms, the logistical
burden of intensive surveillance and the variability of diarrhoea
in space, time and person.
Methods We review current practices in sampling procedures to measure
diarrhoea, and provide guidance for diarrhoea measurement
across a range of study goals. Using 14 available data sets, we
estimated typical design effects for clustering at household and vil-
lage/neighbourhood level, and measured the impact of adjusting for
baseline variables on the precision of intervention effect estimates.
Results Incidence is the preferred outcome measure in aetiological studies,
health services research and vaccine trials. Repeated prevalence
measurements (longitudinal prevalence) are appropriate in
high-mortality settings where malnutrition is common, although
many repeat measures are rarely useful. Period prevalence is an
inadequate outcome if an intervention affects illness duration.
Adjusting point estimates for age or diarrhoea at baseline in rando-
mized trials has little effect on the precision of estimates. Design
effects in trials randomized at household level are usually <2
(range 1.0–3.2). Design effects for larger clusters (e.g. villages or
neighbourhoods) vary greatly among different settings and study
designs (range 0.1–25.8).
Conclusions Using appropriate sampling strategies and outcome measures can
improve the efficiency, validity and comparability of diarrhoea stu-
dies. Allocating large clusters in cluster randomized trials is com-
promized by unpredictable design effects and should be carried out
only if the research question requires it.
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Introduction
Diarrhoeal diseases remain a leading cause of morbid-
ity and mortality in children worldwide.1 Reliable
field data from epidemiological studies are required
to study diarrhoea epidemiology and the effect of
interventions,2,3 but diarrhoea remains a condition
difficult to measure.4 Systematic reviews of diarrhoea
interventions have found a great variety of approaches
to measure diarrhoea.5,6 The past decade saw a trend
towards less intensive active diarrhoea surveillance,7
the use of repeated diarrhoea prevalence measures in-
stead of incidence as outcome measure8 and a greater
recognition of recent advances in the design of cluster
randomized trials.9,10 In this article we review current
practices in conducting epidemiological studies on
diarrhoeal diseases with an emphasis on randomized
controlled trials (RCTs) in low-income populations,
including cluster randomized trials. We discuss crucial
methodological problems to be considered in the plan-
ning stage of a trial, but several issues should also be
relevant for observational studies.
Literature search methods and
data sets
We searched the database MEDLINE for the years
1970–2009 without language restrictions, using the
search terms [diarrh(o)ea AND trial], [diarrh(o)ea
AND measurement], [diarrh(o)ea AND recall] and
[diarrh(o)ea AND longitudinal prevalence]. We
screened the reference lists of relevant articles and con-
tacted authors and experts in the field for further iden-
tification of relevant articles. We further used original
data sets from different field sites across the world (in
part described previously11) to address issues of design
effect and adjustment for baseline variables in RCTs.
These data sets came from the authors of this article or
were made available to us by other researchers in the
field (see ‘Acknowledgements’).
Reporting and recording diarrhoea symptoms
Case definitions for diarrhoea commonly are either
based on reported signs and symptoms (stool fre-
quency, presence of blood or mucus) or based on
local disease perception. For example, a study in
Ghana identified seven different local terms for symp-
toms compatible with diarrhoea.12 Relying on local
disease definitions requires extensive qualitative re-
search and piloting,13 but such work can provide im-
portant insights that are useful for a study as a whole.
Most studies continue to use the WHO definition of
diarrhoea,14 defined as ‘the passage of 3 or more loose
or liquid stools per day, or more frequently than is
normal for the individual’.15,16 A stringent definition
that does not depend on local disease concepts may
reduce subjectivity and perhaps also the risk of bias
but this has not yet been shown in practice. While not
necessarily having more clinical validity, using the
WHO definition facilitates comparison across sites
(Box 1). Asking study participants specifically for
the presence or absence of ‘3 or more loose or liquid
stools per day’ may unnecessarily force a decision by
the respondent that may be prone to bias. Therefore,
some diarrhoea trials record stool frequency and then
apply the WHO definition post-hoc.17,18
Studies have shown that the longer the recall
period, the greater the imprecision (especially under-
estimation) of prevalence estimates.13,19–23 By assum-
ing that reported prevalence in the last 24 h was 100%
accurate, these studies may have overestimated recall
error, since the higher diarrhoea prevalence closer to
the day of the visit may indicate that people remem-
ber diarrhoea during the past 7 days as having
occurred more recently than was actually the case.
In a study from Peru, mothers reported the correct
prevalence of diarrhoea but often were inaccurate in
reporting the exact day when it occurred.24 Recall
error depends on the severity and duration of symp-
toms.23 A decline in reported diarrhoea with time on
study (independent of treatment) has been noted in
diverse populations.10,25–29 Intensive surveillance
including frequent home visits can lower the reported
diarrhoea prevalence,30 perhaps due to ‘reporting
fatigue’. Recall can be more complete in groups of
higher socio-economic status, leading to bias when
comparing different populations.31
Recall error may not be a big problem in studies
exploring disease trends or comparing diarrhoea risk
between treatment arms, if it can be assumed that
recall error is non-differential among the groups com-
pared. This assumption, however, is difficult to verify
in unblinded trials. There are numerous theoretical
possibilities for treatment effects to be biased. For ex-
ample, allocation to the control group may lead to
diarrhoea episodes being remembered more acutely
out of frustration of not receiving the intervention.
Alternatively, allocation to a treatment group may
lead participants to not report disease episodes or
field staff to not record disease episodes under the
expectation that the intervention is effective. Due to
such biases, even a diarrhoea reduction of 50%
observed in unblinded trials may be compatible with
no true effect.32
Given the complexity of validating reported diar-
rhoeal disease in community-based surveys, investiga-
tors should take steps to minimize measurement error
whenever possible. A 7-day recall period is commonly
used in diarrhoea trials,33 but a shorter recall period
may reduce subjectivity of reporting and possibly bias
in unblinded trials. Using a 2- or 3-day recall often
leads to only a small to moderate loss of power com-
pared with a 7-day recall period, especially if diar-
rhoea is common, if the number of measurements
per individual exceeds 10 or 12 and in cluster rando-
mized trials.34 Instead of asking for diarrhoea in the
previous 24, 48 or 72 h, one could consider asking for
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whole calendar days only (Did you have diarrhoea
today? Yesterday? The day before yesterday?). Such
questions are usually easier to ask and to answer.
Numerous studies have demonstrated that symptom
recall beyond 7 days is unreliable, and we do not rec-
ommend it.13,19–23 In any case, the final choice of the
recall period should only be done after pilot-testing
different approaches in a given setting.
Incidence or longitudinal prevalence as
outcome measure
Diarrhoea can be measured as incidence (new epi-
sodes per person-time) or prevalence (disease pres-
ence at time t, Box 1). Incidence does not account
for episode duration,8 an important risk factor for ad-
verse outcomes.35,36 In settings where diarrhoea is
common, it can be difficult to distinguish one episode
from the next. Two to three days have been suggested
as the most appropriate period to separate distinct
episodes,15,37 an approach widely in use today. If diar-
rhoea is quite rare, it makes sense to use a longer gap
(e.g. 6 days27,38) to separate distinct episodes, since
episodes are unlikely to occur close together by
chance. Such definitions are, to some extent, arbitrary
and will inevitably cause some misclassification.14,39
Methods have been developed to allow the compari-
son of studies using different definitions.14 Measuring
incidence especially in high-risk settings can require
close disease surveillance (e.g. one to three times/
week) to establish beginning and end of episodes.18
However, a rough incidence estimate can be obtained
by repeated period prevalence measurements assum-
ing that diarrhoea preceded by a period without diar-
rhoea represents a new episode.40
Incidence is an appropriate measure if the duration
of illness is not of particular interest. A new episode
can be interpreted as a case of pathogen transmission
to a new host, which for disease control or vaccine
research can be more important than episode
duration. This applies to disease surveillance in
middle- and high-income settings with low risk of
malnutrition and diarrhoea-related mortality. For ex-
ample, a study in the UK compared the incidence of
diarrhoea in the community with cases reported to
surveillance agencies.41 The duration of episodes was
of little importance. Health service and vaccine re-
searchers are often more interested in incident epi-
sodes than prevalence, focusing on the incidence of
episodes with pre-defined characteristics, e.g. episodes
of long duration or with blood/mucus, or watery diar-
rhoea for the surveillance of cholera.36,42 Such studies
often use passive case finding instead of intensive
active surveillance, e.g. by measuring the incidence
of hospital admissions. This approach allows obtain-
ing detailed clinical data and causative agents as-
sessed by health professionals, often at a higher
standard compared with field data. Measuring the in-
cidence of hospital admission biases the data towards
severe episodes, which are often the episodes of
highest public health interest. Since only a fraction
of diarrhoea episodes are seen at hospitals, the
study population receiving the intervention will have
to be large. On the other hand, there is no need for
repeated surveillance visits. Passive recording of the
incidence of hospital admissions may be less prone
to observer and responder bias than diarrhoea inci-
dence recorded through active surveillance because,
although bias cannot be excluded, study participants
are less likely to decide on health-care use based on
treatment allocation. If the aim of a study is to obtain
detailed clinical data on all, not just severe, episodes,
close active surveillance (e.g. contacting participants
at least once a week) is usually required, especially
if stool samples are collected.41
Outside clinical studies, prevalence rather than inci-
dence is often the outcome measure of choice, espe-
cially if prevalence can be measured repeatedly in the
same individual. Repeated measurements provide an
estimate of an individual’s proportion of time ill, also
termed ‘longitudinal prevalence’ (LP).8 The ideal set-
tings for using LP as outcome are low-income, high-
risk populations where preventing adverse outcomes
such as death and malnutrition is important. LP is a
better predictor of such complications than inci-
dence.8,43 Table 1 shows the results from two large
RCTs conducted in Guatemala44 (Household water
treatment intervention) and Brazil17 (Vitamin A sup-
plementation). In the Guatemala trial, the interven-
tions reduced the incidence of diarrhoea by 24%,
whereas the mean LP (days with diarrhoea/days
observed) was reduced by only 14%. This was because
the intervention mostly prevented short episodes.44 In
contrast, the Brazil study achieved only a small reduc-
tion in the incidence, which, however, masks the
impact of the intervention on the duration of illness,
leading to an LP reduction of 12% (note the differ-
ences in the P-values for LP vs incidence). In both
cases it can be argued that longitudinal prevalence
is the more appropriate way to measure public
health impact.
Individuals tend to differ more in the number of
disease days than in the number of episodes they ex-
perience, since the variation in the duration of epi-
sodes increases the standard deviation (SD) of LP
compared with incidence.11 LP studies may require a
larger sample size than incidence studies, if the
Table 1 Incidence vs longitudinal prevalence of diarrhoea:
impact on study results and interpretation in two
randomized trials
Incidence
reduction (%) P
Mean LP
reduction (%) P
Guatemala (n¼ 2982)
Water treatment 24 0.001 14 0.185
Brazil (n¼ 1180)
Vitamin A 7 0.18 12 0.06
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exposure variable has no effect on episode duration.34
If, however, the exposure variable is associated with
shorter episodes (as in the Brazil Vitamin A study),
using LP increases power because the effect size
should be larger (Table 1). If an intervention reduces
predominantly short episodes as in Guatemala
(Table 1), incidence may be more powerful, but may
also be less informative for public health purposes.
Table 2 summarizes advantages and disadvantages
of using incidence vs prevalence measurements.
At what intervals should diarrhoea
prevalence be measured?
Diarrhoea prevalence can be measured at long and
irregular intervals because a prevalence measurement
requires no information of when an episode started.
Incidence may also be estimated by infrequent or ir-
regular sampling, e.g. by assuming that any diarrhoea
occurring within the recall period is a new episode if
no diarrhoea was present early in the recall period.
This, however, is when recall error may be greatest,
making such incidence estimates potentially
unreliable.
Infrequent sampling can reduce costs34 and may
increase validity, since frequent measurements may
compromise the willingness of participants to report
illness. Frequent measurements may lead to a better
compliance with the intervention and a lower re-
ported prevalence of diarrhoea, at least if each visit
includes procedures that are clearly related to the
intervention (e.g. water testing in a household water
chlorination intervention30).
Many repeat measurements of diarrhoea prevalence
often provide little additional study power compared
with fewer measurements.34 Clustering of disease in
high-risk individuals means that if an individual re-
ports being diseased at the time of a survey, he/she is
more likely to have been ill on any other day than an
individual reported healthy. The more illness is clus-
tered in individuals, the more disease absence or
presence in an individual at one point in time is rep-
resentative of the true disease experience. Consider as
an example, a study in which weekly surveillance
visits are conducted over 1 year, each time recording
the daily point prevalence of diarrhoea over the past
7 days since the last visit (a 1-week recall period), an
approach resulting in continuous daily diarrhoea data.
It has been shown that a study in which visits are
conducted every 4 weeks instead of every week (again
using a 1-week recall period) only requires a 15–30%
larger sample size, while reducing the number of
visits by 75%.34 In cluster randomized trials, the
sample size increase in this example would even be
smaller.34 Many measurements in the same cluster
(e.g. more than 12 per year) yield little additional
power,45 especially if within-cluster correlation of dis-
ease or cluster size is large.34
Of note, studies using diarrhoea as the ‘exposure’
variable require more precise estimates of an individ-
ual’s burden of diarrhoea than studies with diarrhoea
as ‘outcome’.46 For example, many studies have
examined the effect of diarrhoea LP (the exposure
variable) on mortality,8 malnutrition43,47–52 or the
risk of other infectious diseases (the outcomes).53,54
Imprecision in the measurement of diarrhoea as an
‘exposure’ variable (e.g. due to infrequent sampling)
usually biases the effect estimate towards no effect
(‘regression dilution bias’).55 Often, more than 15 to
20 visits will be required to limit bias.46 Also, when
measuring diarrhoea as an ‘exposure’ variable, a short
Table 2 Comparison between incidence and longitudinal prevalence
Incidence LP
Suitable setting Low diarrhoea risk High diarrhoea risk
Malnutrition and case fatality
uncommon
Malnutrition and case fatality a public
health problem
Suitable research objectives Disease surveillance and control Burden of disease
Health services research Adverse outcomes
Vaccine research Nutrition studies
Aetiological research
Data interpretation Disease transmission Burden of disease
Risk of adverse outcomes
Definition to separate episodes Required Not required
Sampling frequency Usually requires frequent and regular
sampling, unless passive surveillance
is used
Sampling at long or irregular intervals
possible and often logistically
efficient
Study power Larger than for LP if exposure or
treatment has no effect on episode
duration
Larger than for incidence if exposure
or treatment reduces episode
duration
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recall period (e.g. 3 days) may be preferable to min-
imize bias.46 If diarrhoea is the ‘outcome’ measure,
imprecise diarrhoea estimates due to infrequent
visits will only affect the precision of the effect esti-
mate, not the effect size.55
Temporary absence of study participants and logis-
tical constraints can cause prevalence measurements
to be taken at irregular intervals. This is not a prob-
lem if irregularity occurs at random or at least simi-
larly between comparison groups, which often should
be the case. The later analysis should be weighted by
the number of measurements in an individual.56
Point prevalence vs period prevalence
While some investigators choose to record point
prevalence (‘On which of the last X days did you
suffer from diarrhoea?’), others collect period preva-
lence data (‘Did you have diarrhoea at any time
during the last X days?’, Box 1). Period prevalence
data are often used in large demographic and health
surveys. Recording period prevalence may be simpler,
but can reduce the difference (if expressed as a preva-
lence ratio) between two study groups because an
individual with an episode several days long may be
recorded as having the same disease experience as a
person in the other group with only 1 disease day, i.e.
period prevalence data bias the prevalence ratio to-
wards no effect, especially if the disease is common
(e.g. more than five episodes per person-year).34
Perhaps counter-intuitively, period prevalence as an
imprecise outcome measure can achieve a higher
study power than point prevalence even if the recall
period is the same, because differences between indi-
viduals (i.e. the coefficient of variation of the mean
LP) are reduced.34 However, period prevalence data
are inappropriate to capture changes in illness dur-
ation. Effect sizes will be strongly biased towards no
effect if an intervention primarily works by reducing
episode duration,34 and will be exaggerated if an
intervention primarily reduces short episodes
(Table 1, Guatemala study).
To conclude, investigators need to balance the ad-
vantages of using period prevalence data (easy to col-
lect, slightly more powerful in many situations) with
the risk of bias, which depends on the effect of the
factor under study on illness duration. The collection
of daily point prevalence with a limited recall period
provides flexibility to use either outcome measure, but
investigators should specify in advance which is to
serve as the main study outcome to protect against
selectively choosing a measure that provides the result
most aligned with the investigators’ pre-conception.
Adjusting for baseline diarrhoea and age
In many trials, investigators measure diarrhoea at
baseline (before randomization). In general, baseline
measurements in trials may serve to (i) verify ran-
domization success, (ii) adjust the final analysis for
imbalances and (iii) increase precision of the
treatment effect by including the baseline measure
as a covariate in an adjusted analysis. The latter two
uses require that the baseline measure be strongly
associated with the later outcome to be effective.57,58
Concerns over imbalances in diarrhoea prevalence at
baseline have in the past prevented or severely delayed
publication of trials.59 However, caution is warranted
in interpreting baseline diarrhoea data, specifically
when used to verify the success of randomization.
Most demographic variables commonly assessed at re-
cruitment, such as date of birth, gender, family size or
socio-economic status, do not change rapidly (if at all)
and may later be used to adjust for imbalances. In
contrast, diarrhoea prevalence is highly variable over
time.60 If an individual has diarrhoea at baseline, it
indicates that they may be more prone to diarrhoea
during the follow-up period, but this depends on the
within-person clustering of disease in a given setting.
Typically, diarrhoea trials are designed to detect a cer-
tain difference between trial arms given a pre-specified
number of repeat measurements (often more than 10),
assuming a chance of false positivity of, say 0.05. A
‘single’ measurement at baseline in the same number
of people has a considerable chance of suggesting a
relevant imbalance where there may be none. It has
been suggested that multiple baseline measurements
collected during a run-in period could improve the
efficiency of studies with both continuous and inci-
dence rate outcomes,61 but this may not necessarily
apply to diarrhoea. For example, Figure 1 plots the
village-level diarrhoea incidence in 11 control villages
from a randomized trial of solar water disinfection in
Bolivia. The baseline diarrhoea measurement included
6 weeks of surveillance (six measurements per indi-
vidual) that were collected 6 months before the inter-
vention. As Figure 1 illustrates, baseline incidence
bears no relation to incidence during the year-long
intervention period. Several factors may have contrib-
uted to this, such as the long gap between baseline
measurement and the actual trial and, in particular,
the high spatial and temporal variability of diarrhoea
often observed in the field.60 This contrasts with
strong associations between baseline village HIV
prevalence and subsequent incidence,62 or between
baseline height-for-age Z-scores and subsequent
height measurements.63
Table 3 shows the effect of adjusting for baseline
diarrhoea (single measurement) or age on the effect
estimate and standard error (SE) in studies available
to us (age usually is a strong predictor of diarrhoea).
In some cases, adjusting for baseline diarrhoea or age
can have a relevant effect on the effect estimates (e.g.
Kenya and Colombia), and often reduces the SE.
However, adjusting for covariates in RCTs by using
statistical models in general can lead to bias, and
should be conducted with caution.64 The protocol for
adjusted analyses in randomized trials to gain study
power or reduce bias should be pre-specified58 and
reserved for large studies, where statistical models
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may be less biased.64 The age adjustments shown in
Table 3, however, do not suggest a great gain in study
power in large studies. In cluster randomized trials
the gain in power due to baseline adjustment may
be even lower than in individually randomized
trials, especially if the between-cluster variation is
high.57 Based on these results and Figure 1, we
infer that baseline diarrhoea would make a poor
matching or stratification variable in a trial’s design.
To conclude, a single baseline measurement of diar-
rhoea should primarily be useful to confirm trial pro-
cedures and familiarize study participants and field
Table 3 Effect of adjusting for baseline diarrhoea or age on point estimate and SE
References Country
Age range
(years) N
Crude analysis Adjusted analysis
SE change (%)PR SE P PR SE P
Adjustment for baseline diarrhoea
Clasen et al.65 Bolivia 0–80 317 0.55 0.16 0.042 0.52 0.16 0.038 þ1
Boisson et al.66 Congo 0–84 1144 0.85 0.15 0.336 0.88 0.15 0.447 þ1
Colford et al.67 USA 55–95 770 0.90 0.06 0.119 0.90 0.06 0.123 þ0.1
Clasen et al.68 Colombia 0–82 684 0.54 0.14 0.017 0.54 0.13 0.015 1
Boisson et al.69 Ethiopia 0–91 1516 0.75 0.09 0.011 0.74 0.08 0.007 3
Trotta59 Peru 0.5–1.5 483 0.98 0.20 0.902 1.03 0.18 0.850 9
Tiwari et al.70 Kenya <15 216 0.37 0.13 0.004 0.31 0.12 0.002 9
Adjustment for age
Tiwari et al.70 Kenya <15 216 0.37 0.13 0.004 0.37 0.13 0.005 þ1
Colford et al.67 USA 55–95 770 0.90 0.06 0.119 0.91 0.06 0.129 þ0.3
VAST12 Ghana 0–5 1918 0.99 0.01 0.316 1.01 0.01 0.289 1
Reller et al.44 Guatemala 0–80 2980 0.86 0.08 0.106 0.86 0.08 0.112 2
Boisson et al.69 Ethiopia 0–91 1516 0.75 0.09 0.011 0.75 0.08 0.009 3
Boisson et al.66 Congo 0–84 1144 0.85 0.15 0.336 0.88 0.14 0.434 3
Clasen et al.68 Colombia 0–82 684 0.54 0.14 0.017 0.43 0.13 0.010 6
Clasen et al.65 Bolivia 0–80 317 0.55 0.16 0.042 0.48 0.12 0.005 23
Age adjustment was made with age as categorical variable (<1 year, 1 to <2 years, 2 to <3 years, 3 to <5 years, 5 to <10 years,
10 to <15 years, 515 years), except for the US elderly population (55–64, 65–74, 75–84 and 85–95 years); PR, prevalence ratio.
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Figure 1 Village-level diarrhoea incidence during a 12-month follow-up period in 11 control villages that participated in an
intervention trial of solar water disinfection.10 Vertical lines mark bootstrapped 95% confidence intervals. The follow-up
incidence is plotted against baseline incidence measured over a 6-week period (A), and against the village rank in baseline
incidence over that same period (B)
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staff with measurement procedures. Occasionally, it
has been observed that the first or a single measure-
ment in a trial may provide implausibly high
estimates compared with follow-up visits.66,71,72
Participants concerned about potentially not being
included in a trial may over report the disease at
first visit. A baseline measurement that would not
be included in a later analysis may limit the impact
of this possible effect.
Group-level clustering and design effect
Many diarrhoea studies need to consider clustering of
diarrhoea in households or villages/neighbourhoods,
e.g. if an intervention is randomized at group level.
The effect of clustering can be expressed as the design
effect DEFF, the factor by which the sample size
needs to be increased to account for clustering:73
DEFF ¼ 1 þ ðm 1Þ  ICC
where m is the number of individuals per cluster,
and ICC is the intra-cluster correlation coefficient.9
Estimating ICC and DEFF is one of the most challen-
ging aspects in complex diarrhoea trials. Both depend
on factors such as (i) mean number of persons per
cluster, (ii) mean number of measurements per
person, (iii) within-person correlation of diarrhoea
(which strongly depends on the age range included)
and (iv) the differences in diarrhoea risk between
clusters (i.e. the between-cluster variability). In
areas where a substantial proportion of diarrhoea
occurs as localized epidemics shifting from place to
place, between-cluster variability (i.e. ICC and
DEFF) will be high because some areas may be
experiencing an outbreak at the time of study, where-
as others are not. In addition, the DEFF increases if
cluster size and number of measurements per individ-
ual vary,74 which is usually the case in field studies.
Calculating the DEFF for diarrhoea as a binary out-
come based on an ICC estimate is not straightforward,
perhaps best highlighted by the many different meth-
ods available.75,76 Estimating the ICC treating diarrhoea
LP as a continuous outcome is problematic since
follow-up time usually differs between individuals.
Alternatively, the DEFF can be estimated directly
from the SEs of the log prevalence ratio or log rate
ratio resulting from clustered and unclustered
analyses:9
DEFF ¼ SE
2
clustered
SE2unclustered
where SEclustered is the standard error from an ana-
lysis accounting for clustering, and SEunclustered is the
standard error from an analysis ignoring clustering.
We calculated DEFFs from the data of several rando-
mized trials available to us using this formula (for
details, see footnote of Table 4). We calculated
DEFFs separately for within-person and within-
cluster correlation of disease to show the effect of
group-level clustering in addition to the design
effect due to within-person correlation.
DEFFs for ‘household’ clustering are quite similar
across studies, ranging from one to approximately
three regardless of the study design (Table 4). In con-
trast, we found very different design effects of up to
22 if the unit of clustering was large (villages or
neighbourhoods). In one case (urban Brazil), the
design effect was much smaller for the analysis ac-
counting for neighbourhood clustering compared with
the analysis accounting for within-person clustering
only. In this setting an individually randomized trial
may require a larger sample size than a cluster ran-
domized trial, because children in the same cluster
had very different diarrhoea risks, whereas the
cluster-level diarrhoea risks were similar. For six stu-
dies with continuous diarrhoea records we did the
same calculation for incidence of new episodes
[Table 4, DEFFs in brackets], mostly resulting in
much lower within-person DEFFs and slightly
higher household DEFFs compared with prevalence
data. The DEFFs for incidence vs prevalence due to
village/neighbourhood clustering were quite different
in three of the six studies (rural Bolivia, rural
Pakistan and urban Brazil).
Overall, DEFFs in trials randomizing large clusters
are difficult to predict unless previous data from the
same site are available. Randomization of large clus-
ters should perhaps be ‘avoided like the plague’ unless
the research question requires it.77
The DEFFs due to ‘within-person’ correlation very
strongly depend on the number of measurements
(Table 4), showing again that many repeated meas-
urements contribute little to study power. Continuous
surveillance of daily point prevalence generally results
in extremely large within-person DEFFs because of
high day-to-day correlation. DEFFs are much reduced
if measurements are either reduced to period preva-
lence, or separated by intervals between measure-
ments. Repeat measures add to the complexity of
sample size calculations for cluster randomized diar-
rhoea trials, since the number of measurements also
affects ‘group level’ ICC and hence DEFF.34 Sample
size calculations for diarrhoea trials may have to be
pragmatic and, even more so than for diseases that do
not recur, undergo an iterative process testing differ-
ent sampling intervals and cluster sizes. Several
approaches are available.9 If diarrhoea is common, it
can make sense to treat diarrhoea as a continuous
variable (e.g. LP or number of episodes per person)
and remove one level of complexity. This requires
knowledge of the mean LP or number of episodes
and the SD given a specified number of measure-
ments (examples have been published elsewhere34).
The sample size resulting from simple formulae
for the comparison of two means73 can be
multiplied by a group-level DEFF deemed appropriate
(Table 4). Note that the presence of several levels
of clustering (e.g. person, household and area) does
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Table 5 Examples of different epidemiological studies and suggested sampling strategy
Study example Suggested sampling strategy
1 Context: RCT of household level food hygiene
promotion to reduce the burden of diarrhoea,
delivered by community health workers to mothers
of young children
Study population: children aged <5 years
Logistics: adequate budget, trained staff and large
eligible population available
Outcome measure: LP
Surveillance duration: 1 year
Sampling frequency: every 6–8 weeks (6–9 contacts)
Recall period: 3 days
Data type: point prevalence
Comment:
Incidence is not suitable as the treatment aims to
lower disease burden, for which LP is likely to be a
better measure
Sampling at intervals (with a corresponding increase
in the overall sample size) is chosen to decrease
survey effects and bias.
3-day recall is chosen to minimize recall error.
The study is done over 1 year to study potential sea-
sonal effects in food contamination.
For the sample size within-household clustering can
be ignored as the average number of young children
per household is usually small (less than two).
2 Context: RCT of household level food hygiene pro-
motion to reduce the burden of diarrhoea, delivered
by community health workers to mothers of young
children
Study population: children aged <5 years
Logistics: tight budget, trained staff scarce, large eli-
gible population available
Outcome measure: LP
Surveillance duration: 5 months
Sampling frequency: every 4 weeks (6 contacts)
Recall period: 7 days
Data type: period prevalence
Comment:
Incidence is not suitable as the treatment aims to
lower disease burden, for which LP is likely to be a
better measure. Sampling at intervals (with a cor-
responding increase in the overall sample size) is
chosen to decrease survey effects and bias.
7-day recall (period prevalence) is chosen to maximize
power.
The study is restricted to 5 months because of the
tight budget, focussing on the hot season where
food contamination may be most common.
For the sample size within-household clustering can
be ignored as the number of young children per
household is small
3 Context: RCT of household level food hygiene pro-
motion to reduce the burden of diarrhoea, delivered
by community health workers to mothers of young
children
Study population: children aged <5 years
Logistics: tight budget, trained staff scarce, eligible
population small (e.g. refugee camp)
Outcome measure: LP
Surveillance duration: 5 months
Sampling frequency: every 2 weeks (12 contacts)
Recall period: 3 days
Data type: point prevalence
Comment:
Incidence is not suitable as the treatment aims to
lower disease burden, for which LP is likely to be a
better measure.
Frequent sampling is chosen to make the most of the
small sample size. Short recall (point prevalence) is
chosen to minimize recall error. Because of the short
visit intervals, longer recall periods do not add much
power.56
The study is restricted to 5 months because of the
tight budget, focussing on the hot season where
food contamination may be most common.
For the sample size within-household clustering can
be ignored as the average number of young children
per household is usually small (less than two).
(continued)
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Table 5 Continued
Study example Suggested sampling strategy
4 Context: RCT of a new vaccine against a pathogen
causing severe diarrhoea
Study population: children aged <5 years
Logistics: adequate budget, trained staff and large
eligible population available
Outcome measure: incidence
Surveillance duration: 12 months
Sampling approach: passive surveillance of hospital
admissions
Recall period: Not applicable (NA)
Data type: incidence of severe episodes
Comment:
Incidence is suitable as the treatment aims to lower
disease transmission of a specific pathogen.
Passive surveillance is chosen because a vaccine can
be delivered relatively easily to a large study popu-
lation, focussing on episodes of particular clinical
interest.
Because hospital admissions do not allow estimating
the effect of the vaccine on LP (a better marker for
adverse effects on nutritional status), one could
consider adding a substudy with active surveillance
similar to Example 1, as was done in a Vitamin A
trial in Ghana.12
5 Context: cluster RCT of a large rural sanitation pro-
gramme delivered at village level
Study population: all ages
Logistics: tight budget, trained staff scarce, large eli-
gible population available
Outcome measure: LP
Surveillance duration: 1 year
Sampling frequency: every 6–8 weeks (6–9 contacts)
Recall period: 7 days
Data type: period prevalence
Comment:
Incidence is not suitable as the treatment aims to
lower disease burden, for which LP is likely to be a
better measure.
Sampling at long intervals (with a corresponding in-
crease in the number of included villages) is chosen
to limit the number of surveillance teams and
transport costs. The sampling procedure aims to
measure the outcome in one village per day per
team. In a cluster randomized trial, more frequent
surveillance rounds add relatively little power.
7-day recall (period prevalence) is chosen to maximize
power. Data on 3-day point prevalence can be ob-
tained in addition as a secondary outcome.
The effect of the intervention in children aged <5
years can be a secondary outcome. Because of the
great uncertainties in study power due to the
cluster-design, it is preferable to include all house-
hold members to maximize power. This is specific-
ally the case if there is little reason to assume the
intervention will affect young and older ages
differently.
6 Context: observational study with recurrent infections
as exposure (e.g. to study association between
diarrhoea and reduction in weight-for-age Z-score)
Study population: children aged <5 years
Logistics: adequate budget, trained staff and large
eligible population available
Outcome measure: LP
Surveillance duration: 1 year
Sampling frequency: every 2 weeks (20–25 visits)
Recall period: 3 days
Data type: point prevalence
Comment:
Frequent sampling is chosen to minimize bias towards
no effect. Efforts should be made to keep study
participants happy and interested. Bias is not a great
concern in an observational study without differen-
tial treatment of study participants.
Short recall period is chosen to minimize bias that
could exaggerate the effect size.
(continued)
EPIDEMIOLOGICAL METHODS IN DIARRHOEA STUDIES 1687
not necessarily require accounting for all of them
in a later analysis. In cluster-randomized trials it is
often sufficient to incorporate clustering at the
level of the unit of randomization, i.e. the level of
independence.78 This is because lower-level correl-
ation of disease should increase the between-cluster
variation at higher levels, which increases the SE
accordingly.78
Conclusion
When planning a study that measures diarrhoea, in-
vestigators must jointly consider the interdependent
methodological points we have discussed in this
article, which include recall periods, measures of dis-
ease occurrence (incidence vs prevalence), sampling
frequencies and design effects. For example, the
sampling frequency and the choice of the measure
of disease occurrence can both influence the design
effect. Conversely, the design effect can influence the
choice of the sampling frequency or the recall period,
because a strong design effect limits the study power
gained from frequent sampling and long recall peri-
ods. Further, study settings differ from one another,
especially in their logistics, which in turn has great
implications for the study design. In some places it is
difficult to recruit and train many field workers; in
others it may be difficult to recruit study participants.
As a consequence, it is difficult to develop universally
applicable guidelines or a simple algorithm to identify
the best way to measure diarrhoea in a specific study.
In Table 5 we list examples of diarrhoea studies and
suggest approaches to measure diarrhoea. None of our
suggestions is meant to be absolute. As already sug-
gested by Table 2, investigators must consider the
Table 5 Continued
Study example Suggested sampling strategy
7 Context: observational study41 year, aimed at de-
tailed exploration of clinical features of individual
episodes (e.g. illness duration, severity, clinical signs
and symptoms, stool testing for pathogens)
Study population: children aged <5 years
Logistics: adequate budget, trained staff and large
eligible population available
Outcome measure: incidence
Surveillance duration: 1 year
Sampling frequency: once a week (50 contacts)
Recall period: 7 days
Data type: point prevalence data from which inci-
dence can be calculated
Comment:
Frequent sampling is chosen to accurately establish
the beginning and end of episodes, and to record
clinical signs and symptoms in detail. Efforts should
be made to keep study participants happy and
interested. Bias is not a great concern in an obser-
vational study without treatment allocation of study
participants.
Continuous disease records may be needed, but de-
pending on the budget, the surveillance period can
be cut into blocks of, e.g., 6–8 weeks where sur-
veillance is intense. This could allow capturing dif-
ferent seasons where different pathogens may
circulate (dry cold season, wet season, hot season).
8 Context: demographic and health survey (DHS). The
aim of the survey is to gain information on a range
of topics, but the investigator also wishes to explore
risk factors for diarrhoea (e.g. water, sanitation,
socio-economic status)
Study population: all ages
Logistics: adequate budget, trained staff and large
eligible population available
Outcome measure: LP
Sampling frequency: one visit
Recall period: 2–3 days
Data type: point prevalence
Comment:
A short recall period is preferred to minimize recall
error. A DHS usually aims to estimate prevalence as
an absolute figure, not primarily to compare two
groups, and therefore requires accurate data. Given
the large sample size of most DHS surveys, loss of
power due to a short recall period is normally not a
big issue.
Point prevalence data may often be easier to interpret
and compare with, than period prevalence data,
since diarrhoea definitions used in most DHS and
epidemiological studies are based on disease ex-
perience during one day.
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research question first, as many critical decisions
depend on it. For example, incidence of diarrhoea
(such as hospital admissions) could be the preferred
measure in vaccine trials. Point or period prevalence
measured at long intervals could be ideal for large
environmental health interventions in high-risk popu-
lations where many villages and individuals need to
be surveyed over a long time. A high-risk study popu-
lation here means a setting where malnutrition and
case fatality are a public health problem. Some stu-
dies (such as Demographic and Health Surveys) re-
quire obtaining precise absolute prevalence figures, for
which collecting point prevalence data with a short
recall period is most suitable.
We did not describe a number of important meth-
odological challenges in diarrhoea trials that have
been discussed elsewhere, such as the clinical defin-
ition of disease severity,35,36,42,87,88 or objective proxy
markers for diarrhoea in trials of interventions that
cannot be blinded.89 We also did not discuss recent
advances in diagnostic tools for pathogen identifica-
tion currently in use in some population-based
studies.90
Diarrhoea continues to be a major global health
problem, and there is an ongoing debate over iden-
tifying research priorities and the development of
cheap and effective interventions, given the limited
funding.2,3,91–94 Whereas standard clinical trial pro-
cedures are often adequate to assess the effect of a
vaccine or drug on diarrhoea in individuals, environ-
mental interventions aiming at diarrhoea control are
often much more complex, and more difficult to
evaluate with randomized trials. Efficient methods
to measure diarrhoea should allow more valid and
generalizable results from research to be conducted
with the same resources, especially in settings where
resources are scarce.
Box 1 Definitions
Diarrhoea day Since diarrhoea symptoms occur intermittently, diarrhoea case definitions in epi-
demiology are usually based on the nature and frequency of symptoms experi-
enced during one day (or 24 h). A diarrhoea case is therefore equivalent to a
‘diarrhoea day’. For example, the WHO definition requires the occurrence ‘3 or
more loose or liquid stools per day’.
Diarrhoea episode One or more diarrhoea days occurring closely in time, presumably caused by a single
agent or the interaction of multiple causative agents (e.g. as super-infection).
Defining a diarrhoea episode requires deciding on how many diarrhoea-free days
separate independent episodes. This decision is necessarily pragmatic especially in
high-risk settings, as it is usually difficult to know whether diarrhoea days
occurring closely in time belong to the same episode or not.
Diarrhoea incidence The number of diarrhoea episodes per person-time (incidence density) or over a
defined period of time (cumulative incidence).
Diarhoea point prevalence The proportion of the population experiencing a diarrhoea day at the time of
interest, e.g. the day of a surveillance visit or the day before.
Diarrhoea period prevalence The proportion of the population experiencing at least 1 day with diarrhoea over a
pre-defined time window (recall period) prior to a given point in time, e.g. a
surveillance visit by the study team.
Recall period The period of time over which the occurrence of diarrhoea is assessed at each
contact with a study participant (e.g. phone call or home visit). To measure point
prevalence, the recall period is treated as individual days (for example: ‘on which
of the last 7 days did you have diarrhoea?’). To measure period prevalence, the
recall period is treated as a single time window (e.g. ‘did you have diarrhoea at
any day during the last 7 days?’). Thus, when using a 7-day recall period, a single
surveillance visit yields 7-point prevalence datapoints, but only one period
prevalence datapoint.
Longitudinal prevalence The proportion of time an individual has diarrhoea. This can either be the proportion
of days with diarrhoea (for point prevalence), or the proportion of time windows
with at least 1 diarrhoea day (for period prevalence). For example, a person re-
porting diarrhoea on 10% of days has a longitudinal point prevalence of diarrhoea
of 10%. A person reporting diarrhoea at any time in the last week, in 10% of
weeks of surveillance has a longitudinal period prevalence of 10%. Note that while
prevalence is a population measure of disease occurrence, LP is an individual
measure. A person can have an LP of 10%, but not a prevalence of 10%.
At population level, LP is best described by the mean and SD of individual
LP values.
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KEY MESSAGES
 The design of epidemiological studies on diarrhoea requires specifying recall periods, sampling fre-
quencies and outcome measures that are most suitable to answer the research question in a given
setting.
 Sample size calculations often need to be done based on scarce data. This article outlines how the
validity and logistical efficiency of diarrhoea studies can be improved by careful consideration of
these factors.
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